<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70510">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883141</url>
  </required_header>
  <id_info>
    <org_study_id>iSPOT</org_study_id>
    <nct_id>NCT01883141</nct_id>
  </id_info>
  <brief_title>Left Ventricular MultiSpot Pacing for CRT (iSPOT)</brief_title>
  <acronym>iSPOT</acronym>
  <official_title>Left Ventricular MultiSpot Pacing for CRT (iSPOT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the iSPOT Study is to evaluate the contractility using positive left
      ventricular (LV) dP/dt max across LV pacing site(s) in patients indicated for cardiac
      resynchronization therapy (CRT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multispot LV pacing configuration compared to normal biventricular pacing</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multispot LV pacing configuration compared to normal biventricular pacing in patients undergoing a research study, an electrophysiological exploratory procedure or CRT-implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to normal biventricular pacing</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to normal biventricular pacing in patients undergoing a research study, an electrophysiological exploratory procedure or CRT-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to multispot LV pacing configuration</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in positive left ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to multispot LV pacingin patients undergoing a research study, an electrophysiological exploratory procedure or CRT-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of blood pressure, EGMs and electrocardiographic mapping measurements with the positive LV dP/dt max values</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlate blood pressure, EGMs and electrocardiographic mapping measurements with the positive LV dP/dt max values obtained during each of the three pacing configuration's (BiV, MultiVein and MultiSpot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of non-invasive measurements to identify pacing configuration with highest positive LV dP/dt max</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the non-invasive measurements that are also collected during the study can identify the pacing configuration with the highest positive LV dP/dt max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within patient variability in positive LV dP/dt max</measure>
    <time_frame>Participants will be followed for the time of the EP procedure, which has an average duration of 2 to 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the within patient variability in positive LV dP/dt max measurements</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MultiSpot pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MultiVein pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MultiSpot pacing</intervention_name>
    <description>Subjects will receive pacing from one right ventriclar lead and one left ventricular catheter/lead with multiple LV pacing spots</description>
    <arm_group_label>MultiSpot pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MultiVein pacing</intervention_name>
    <description>Subjects will receive pacing from one right ventriclar lead and two left ventricular catheter/lead(s)</description>
    <arm_group_label>MultiVein pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard biventricular pacing</intervention_name>
    <description>Subjects will receive standard biventricular pacing from one right ventriclar lead and one left ventricular catheter/lead</description>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is indicated for CRT or CRT-D device according to current applicable ESC/AHA
             guidelines

          -  Subject has a left bundle branch block (LBBB) conduction pattern

          -  Subject is in stable sinus rhythm at the time of implant (no atrial arrhythmias
             lasting &gt; 30 seconds during the last 2 weeks prior to inclusion and no documented
             AF-episodes allowed during the last 2 weeks prior to inclusion)

          -  Subject receives optimal heart failure oral medical therapy (ACE inhibitor and/or ARB
             and Beta Blockers), and is on a stable medication scheme for at least 1 month prior
             to enrollment

          -  Subject (or the legal guardian) is willing to sign informed consent form

          -  Subject is 18 years or older or as specified  minimal age per local law/regulation

        Exclusion Criteria:

          -  Subject has permanent atrial fibrillation/ flutter or tachycardia

          -  Subject experienced recent myocardial infarction (MI), within 40 days prior to
             enrollment

          -  Subject underwent coronary artery bypass graft (CABG) or valve surgery, within 90
             days prior to enrollment

          -  Subject is post heart transplantation, or is actively listed on the transplantation
             list

          -  Subject is implanted with a left ventricular assist device (LVAD)

          -  Subject is on chronic renal dialysis

          -  Subject has severe renal disease (defined as estimated Glomerular Filtration Rate
             (equation provided by Modification of Diet in Renal Disease study): (eGFR) &lt; 30
             mL/min/1.73m2)

          -  Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart
             failure (≥ 2 stable infusions per week)

          -  Subject has severe aortic stenosis (with a valve area of &lt;1.0 cm2 or significant
             valve disease expected to be operated within study period)

          -  Subject has complex and uncorrected congenital heart disease

          -  Subject has a mechanical heart valve

          -  Pregnant or breastfeeding women, or women of child bearing potential and who are not
             on a reliable form of birth control

          -  Subject is enrolled in one or more concurrent studies that would confound the results
             of this study

          -  Subject is already implanted with a device
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joeri Heynens, Msc, Ir.</last_name>
    <phone>+31(0)43 3566634</phone>
    <email>joeri.heynens@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Vanderheyden, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Marc Vanderheyden, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic van Heuverswyn, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Frederic Van Heuverswyn, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Choroby Wieńcowej</name>
      <address>
        <city>Warsaw</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maciej Sterliński</last_name>
    </contact>
    <investigator>
      <last_name>Maciej Sterliński</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Zaburzeń Rytmu Serca</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrzej Przybylski</last_name>
    </contact>
    <investigator>
      <last_name>Andrzej Przybylski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Zabrze</city>
        <zip>44-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Kalarus, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Zbigniew Kalarus, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys and St. Thomas NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE 1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Rinaldi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Aldo Rinaldi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 I NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
